PegBio Co., Ltd., a specialist in endocrine metabolism based in Suzhou, has taken a significant step towards going public with an initial public offering (IPO) filing to the Hong Kong Stock Exchange (HKSE). While the price and other specific details of the offering are yet to be disclosed, the move marks a pivotal moment for the company as it seeks to expand its reach and capitalize on its innovative drug development.
Company Background and Focus
Founded in 2008, PegBio is a biotechnology company dedicated to the in-house discovery and development of peptides and small molecule drugs for chronic diseases, with a particular focus on metabolic disorders. The company’s commitment to addressing unmet medical needs in endocrine metabolism is evident in its robust product pipeline, which includes one core product and five additional candidate drugs targeting conditions such as type 2 diabetes (T2DM), obesity, nonalcoholic steatohepatitis (NASH), opioid-induced constipation (OIC), and congenital hyperinsulinemia.
Pipeline Highlights and Core Product
The company’s flagship product, PB-119, an in-house developed long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, is on the cusp of commercialization. Its New Drug Application (NDA) for the treatment of T2DM was accepted for review in China in September of the previous year. PB-119 has demonstrated significant benefits in blood glucose control, cardiovascular health, and weight management across multiple clinical trials, positioning it as a promising treatment option for patients with T2DM.-Fineline Info & Tech
Leave a Reply